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Mean persistence (days) was 219.7 for QTP, 200.9 for OLZ,
194.8 for RIS, and 179.2 for typical antipsychotics. Kaplan-
Meier survival curves for the typical antipsychotic group showed
that hazards of therapy modiﬁcation differed within 250 days of
antipsychotic initiation compared with after 250 days of therapy.
Extended Cox regression modeling indicated no signiﬁcant dif-
ferences between antipsychotics in hazards of therapy modiﬁca-
tion within 250 days of initiation. However, patients initiated on
typical antipsychotics were 6.3 times more likely to modify
therapy compared with those initiated on QTP after 250 days of
antipsychotic therapy (p < 0.0001). CONCLUSIONS: Adher-
ence and persistence were similar between atypical antipsychotic
groups. The typical antipsychotic group, however, demonstrated
lower adherence and a greater likelihood of modifying therapy
than the quetiapine cohort.
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OBJECTIVES: To compare annual mental health service utiliza-
tion patterns by level of adherence with antipsychotic medica-
tion in the naturalistic treatment of schizophrenia. METHODS:
Data were drawn from a large prospective naturalistic study of
treatment for patients with schizophrenia in the U.S, conducted
between July 1997 and September 2003. Detailed mental health
resource utilization was systematically abstracted from medical
records and augmented with patients’ self report. Annual 
medication possession ratio (MPR) with any antipsychotic was
calculated, and each participant was categorized into 1 of 3
adherence groups: adherent (MPR >= 80%, N = 1758), partially
adherent (60% ≤ MPR < 80%, N = 36), and non-adherent (MPR
< 60%, N = 216). RESULTS: Adherent participants were least
likely to have any psychiatric hospitalization and emergency
room visits (p < 0.05). Compared to non-adherent, adherent 
participants were also signiﬁcantly more likely to be engaged in
outpatient treatment processes as evident by greater likelihood
of participation in any psychosocial group intervention (p <
0.05) and in any medication management with psychiatrists (p
< 0.05). CONCLUSIONS: Medication adherence levels are asso-
ciated with differential use of psychiatric services. Adherence
appears to be associated with lower risk of hospitalization and
emergency room visits and greater engagement in the outpatient
treatment processes.
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OBJECTIVES: Compare discontinuation patterns across atypi-
cal antipsychotic agents within the ﬁrst year after initiating
therapy among Medicaid patients with schizophrenia.
METHODS: Adult Medicaid recipients diagnosed with schizo-
phrenia and having atypical antipsychotic drug prescription
claims between July 1, 2001 and September 30, 2003 were cat-
egorized into ﬁve groups of initial antipsychotic drug received:
aripiprazole (n = 446); olanzapine (n = 1705); quetiapine (n =
1467); risperidone (n = 1580); and ziprasidone (n = 700). Dis-
continuation was measured using reﬁll patterns, allowing 14-day
gaps between expected reﬁll dates, and compared across starting
drug groups using Chi-Square tests. Multivariate Cox propor-
tional hazards models then explored the simultaneous impact of
age, gender, race, hospitalization in the 6 months prior to initial
therapy, and other concurrent antipsychotic drug use when 
initiating therapy, in addition to being on any one of the ﬁve
mutually exclusive drug groups, on discontinuation. Sensitivity
analysis tested the robustness of results using longer allowable
prescription gaps between reﬁlls, and examining multiple
episodes of atypical antipsychotic use by using different deﬁni-
tions of the index date. RESULTS: Patients starting treatment on
either aripiprazole, risperidone, or ziprasidone were not signiﬁ-
cantly different from olanzapine [HR 1.047, 0.973 and 0.990,
respectively] with respect to discontinuation of therapy. 
Quetiapine was associated with signiﬁcantly higher hazard of
discontinuation [HR 1.130, p = 0.0044] compared to olanzap-
ine. Other covariates associated with signiﬁcantly lower discon-
tinuation rates were being male [HR 0.899, p = 0.0008], older
age [HR 0.997, p = 0.0348] and being on concurrent medication
when initiating therapy [HR 0.225, p < 0.001]. Having previous
hospitalization was associated with signiﬁcantly higher discon-
tinuation rate [HR 1.276, p < 0.001]. These results were robust
across sensitivity analyses. CONCLUSIONS: Patients initiating
on ziprasidone, aripiprazole, risperidone and olanzapine had
similar discontinuation at one year. The higher hazard associated
with quetiapine is consistent with the higher rate of discontinu-
ation observed for quetiapine when compared to olanzapine in
Phase I of the CATIE trial.
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OBJECTIVES: To determine the compliance and persistence to
atypical antipsychotics in the treatment of schizophrenia patients
and associated health care utilization. METHODS: The study
sample was based on NC Medicaid claims database. Patients were
included if they had a diagnosis of schizophrenia (ICD-9 295.XX),
received at least two antipsychotic prescriptions during the period
after index date and were continuously enrolled in NC Medicaid
Program during three month prior and one year post treatment
periods. Medication possession ratio (MPR), persistence and
medication use gap were used as compliance measures. Both
descriptive and multivariate model were conducted. RESULTS:
A total of 450 patients were included. Mean age was 42.3 years.
52.4% were men and 33.1% were blacks. Adherent (0.8 <= PR
<= 0.1), non-adherent (MPR < 0.8) and over-adherent (MPR >
1.1) patients accounted for 34.8%, 45.3%, and 18.9% respec-
tively. Approximately 42.4% of patients had medication use gap,
and the average duration of continuous medication use was 229
days. Adherent patients had fewer hospital admissions and hos-
pital days than nonadherent and overadherent patients (0.57 vs.
1.0 vs. 0.82 admissions; 5.2 vs. 10.0 vs. 5.9 days). Patients with
gaps in medication use had more hospital admissions and hospi-
tal days than those without gaps (1.1 vs. 0.64 admissions; 10.4
vs. 5.3 days). In terms of the risk of hospitalization, nonadher-
ent patients were more likely to be hospitalized than adherent
ones (OD: 1.694, 95% CI: 1.019–2.816). Patients with gaps in
medication use were more likely to be hospitalized (OD: 2.589,
95% CI: 1.633–4.106) and had 11 more hospital days than those
without a gap (p = 0.0275). Patients who stayed on medication
longer were less likely to be admitted to hospitals (OD: 0.998,
95% CI: 0.997–0.999). CONCLUSIONS: The results from this
